Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Virpax Pharmaceuticals (VRPX) is exploring the use of Molecular Envelope Technology (MET) or similar technology to develop an intranasal mRNA COVID vaccine. The company aims to create a needle-free delivery system similar to FluMist, utilizing non-lipid polymer technology that may offer improved safety and reduced side effects compared to current lipid-based delivery systems.
The company currently employs MET in two other products: Envelta (NES100), an enkephalin-based drug product using nanotechnology for enhanced brain delivery, and NobrXiol (VRP324), a cannabidiol treatment for epilepsy that uses MET to cross the blood-brain barrier through nasal delivery. NobrXiol has received pre-IND guidance from the FDA.
Virpax Pharmaceuticals (VRPX) sta esplorando l'uso della Tecnologia Molecolare a Involucro (MET) o tecnologie simili per sviluppare un vaccino COVID mRNA intranasale. L'azienda mira a creare un sistema di somministrazione senza aghi simile a FluMist, utilizzando una tecnologia a base di polimeri non lipidici che potrebbe offrire una maggiore sicurezza e ridurre gli effetti collaterali rispetto ai sistemi di somministrazione basati su lipidi attualmente in uso.
L'azienda utilizza attualmente la MET in altri due prodotti: Envelta (NES100), un prodotto farmaceutico a base di enkephalina che utilizza nanotecnologie per migliorare la somministrazione al cervello, e NobrXiol (VRP324), un trattamento a base di cannabidiolo per l'epilessia che utilizza la MET per attraversare la barriera emato-encefalica attraverso la somministrazione nasale. NobrXiol ha ricevuto indicazioni pre-IND dalla FDA.
Virpax Pharmaceuticals (VRPX) está explorando el uso de la Tecnología de Envoltura Molecular (MET) o tecnologías similares para desarrollar una vacuna COVID de ARNm intranasal. La empresa tiene como objetivo crear un sistema de entrega sin agujas similar a FluMist, utilizando tecnología de polímeros no lipídicos que podría ofrecer una mayor seguridad y reducir los efectos secundarios en comparación con los sistemas de entrega basados en lípidos actuales.
Actualmente, la empresa emplea MET en otros dos productos: Envelta (NES100), un producto farmacéutico basado en enkephalina que utiliza nanotecnología para mejorar la entrega al cerebro, y NobrXiol (VRP324), un tratamiento con cannabidiol para la epilepsia que utiliza MET para cruzar la barrera hematoencefálica a través de la entrega nasal. NobrXiol ha recibido orientación pre-IND de la FDA.
Virpax Pharmaceuticals (VRPX)는 분자 외피 기술(MET) 또는 유사 기술을 활용하여 비강 내 mRNA COVID 백신을 개발하는 방안을 모색하고 있습니다. 이 회사는 FluMist와 유사한 바늘 없는 전달 시스템을 만들고자 하며, 현재의 지질 기반 전달 시스템에 비해 향상된 안전성과 감소된 부작용을 제공할 수 있는 비지질 폴리머 기술을 활용하고 있습니다.
현재 이 회사는 MET를 두 가지 다른 제품에 사용하고 있습니다: Envelta (NES100), 향상된 뇌 전달을 위해 나노기술을 사용하는 엔케팔린 기반 약물 제품, 그리고 NobrXiol (VRP324), 비강 전달을 통해 혈액-뇌 장벽을 통과하기 위해 MET를 사용하는 간질 치료용 칸나비디올입니다. NobrXiol은 FDA로부터 사전 IND 지침을 받았습니다.
Virpax Pharmaceuticals (VRPX) explore l'utilisation de la Technologie de l'Enveloppe Moléculaire (MET) ou de technologies similaires pour développer un vaccin COVID à ARNm intranasal. L'entreprise vise à créer un système de livraison sans aiguille similaire à FluMist, utilisant une technologie de polymères non lipidiques qui pourrait offrir une sécurité améliorée et réduire les effets secondaires par rapport aux systèmes de livraison basés sur des lipides actuellement utilisés.
L'entreprise utilise actuellement la MET dans deux autres produits : Envelta (NES100), un produit pharmaceutique à base d'enképhaline utilisant la nanotechnologie pour améliorer la livraison au cerveau, et NobrXiol (VRP324), un traitement à base de cannabidiol pour l'épilepsie qui utilise la MET pour traverser la barrière hémato-encéphalique par voie nasale. NobrXiol a reçu des conseils pré-IND de la FDA.
Virpax Pharmaceuticals (VRPX) erkundet den Einsatz der Molekulare Hüllentechnologie (MET) oder ähnlicher Technologien zur Entwicklung eines intranasalen mRNA COVID-Impfstoffs. Das Unternehmen hat sich zum Ziel gesetzt, ein nadelfreies Abgabesystem ähnlich wie FluMist zu schaffen, das nicht-lipidische Polymertechnologie nutzt und möglicherweise eine verbesserte Sicherheit sowie reduzierte Nebenwirkungen im Vergleich zu den derzeit verwendeten lipidhaltigen Abgabesystemen bietet.
Das Unternehmen setzt MET derzeit in zwei weiteren Produkten ein: Envelta (NES100), ein auf Enkephalin basierendes Arzneimittel, das Nanotechnologie für eine verbesserte Abgabe an das Gehirn verwendet, und NobrXiol (VRP324), eine Cannabidiol-Behandlung für Epilepsie, die MET nutzt, um die Blut-Hirn-Schranke durch nasale Abgabe zu überwinden. NobrXiol hat von der FDA eine vorläufige IND-Leitlinie erhalten.
- Potential expansion into COVID vaccine market
- Innovative needle-free delivery technology
- Multiple applications of proprietary MET technology
- FDA pre-IND guidance received for NobrXiol
- Early-stage development with no proven efficacy
- Faces competition from established vaccine makers
- No timeline provided for vaccine development
The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune response via injection. Virpax hopes to use a non-lipid polymer, which may be safer and have less side effects.
NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. We believe that the nanotechnology may enable and enhance the delivery of this metabolically labile peptide drug into the brain. In addition, Virpax uses MET with NobrXiol. NobrXiol is being developed for delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the MET as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The drug has received pre-Investigational New Drug application guidance from the
About Virpax Pharmaceuticals Inc.
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com, and follow us on Twitter, LinkedIn and YouTube.
Forward-Looking Statements
This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307334228/en/
Investor Contact:
info@virpaxpharma.com
Source: Virpax Pharmaceuticals, Inc.
FAQ
What is Virpax's (VRPX) new approach to COVID vaccine delivery?
How does Virpax's proposed COVID vaccine technology differ from current vaccines?
What other products is VRPX developing using MET technology?
What regulatory progress has Virpax's NobrXiol made with the FDA?
